Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
News|Articles|February 14, 2019
Aigenpulse Achieves ISO Certification for AI Data Technology
Author(s)Pharmaceutical Technology Editors
Big data technology company, Aigenpulse, has been granted with International Organization for Standardization (ISO) 9001:2015 and ISO 27001:2013 certification.
Advertisement
Big data technology company, Aigenpulse, has been granted with International Organization for Standardization (ISO) 9001:2015 and ISO 27001:2013 certification, which are in recognition of product quality and management of information safely and securely, respectively.
“We are extremely proud of gaining certification to both ISO 9001 and ISO 27001 standards. These certifications underline our commitment to customers and our focus on quality, data security, and reliability,” said Tobias Kloepper, CEO of Aigenpulse, in a Feb. 5, 2019 press release. “As part of implementing a Quality Management System, we have automated all of our compliance processes, which have been designed to drive high quality performance and continuous improvement.”
Assessment of Aigenpulse’s offerings was performed independently by the British Assessment Bureau, which is a certification body. Through the ISO accreditation, Aigenpulse has strengthened its platform offering, which uses artificial intelligence (AI) and advanced machine learning technologies to help researchers analyse data.
“Customers, stakeholders and staff can be reassured that their information is being held and managed securely and that as a management team we take our accountability for protecting our systems and client data very seriously,” Kloepper added.
Source:
Advertisement
Related to this article
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Advertisement
Advertisement